Tevogen Bio Holdings Inc. – NASDAQ:TVGN

Add to watchlist

$0.94

-0.09

-8.75%

Market closed

Open in 2 days

+44.06%

month

+44.06%

quarter

Market Cap	172.82M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Profit margin
2023	0	-67.32K

Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Debt to assets
2023	17037333	17.73M	104.08%

Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Cash Flow
2022	-215.39K	-479	7.5K
2023	-1.37M	342.91M	-341.66M

Tevogen Bio Holdings alternative data

Tevogen Bio Holdings
Employees

Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Employee count
Apr 2024	17
May 2024	17
Jun 2024	17
Jul 2024	17
Dec 2024	17

Tevogen Bio Holdings
Insider Trading

Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Insider trades (number of shares)
Period	Buy	Sel
Jun 2024	5607	0
Oct 2024	0	1078600

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	17 Oct 2024	FLOMENBERG NEAL officer: See Remarks officer: See Remarks	Common Stock	1,078,600	$1.62	$1,747,332
Purchase	12 Jun 2024	DESAI KIRTI officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	3,000	$0.82	$2,460
Purchase	5 Jun 2024	SAADI RYAN H. director, 10 percent owner, officer: Chief E.. director, 10 percent owner, off..	Common Stock	2,607	$0.77	$2,000

TVGN insider trading transactions

Tevogen Bio Holdings
Latest News

Thursday, 26 December 2024
12:21	Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference	globenewswire.com
Monday, 23 December 2024
09:38	Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference	globenewswire.com
Thursday, 19 December 2024
08:30	Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda	globenewswire.com
Wednesday, 18 December 2024
02:29	Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound	seekingalpha.com
Tuesday, 17 December 2024
13:32	Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference	globenewswire.com
Tuesday, 10 December 2024
15:13	Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference	globenewswire.com
Thursday, 5 December 2024
11:03	Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame	globenewswire.com
Tuesday, 26 November 2024
08:05	Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy	globenewswire.com
Thursday, 21 November 2024
15:59	Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value	globenewswire.com
Tuesday, 19 November 2024
16:50	Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model	globenewswire.com
Thursday, 14 November 2024
17:00	UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials	globenewswire.com
15:49	Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials	globenewswire.com
Friday, 8 November 2024
15:36	Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations	globenewswire.com
Tuesday, 5 November 2024
09:27	Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920	globenewswire.com
Monday, 4 November 2024
14:36	Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support	globenewswire.com
Thursday, 31 October 2024
10:54	Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs	globenewswire.com
Tuesday, 29 October 2024
15:28	Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company	globenewswire.com
14:38	Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 Million	globenewswire.com
12:43	Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity	globenewswire.com
Friday, 25 October 2024
17:34	Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas	globenewswire.com
Wednesday, 23 October 2024
08:35	Tevogen Bio's Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development	globenewswire.com
Tuesday, 22 October 2024
14:30	Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week	globenewswire.com
Monday, 21 October 2024
15:58	Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion	globenewswire.com
13:56	Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days	globenewswire.com
Friday, 18 October 2024
22:46	Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company's Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days	globenewswire.com
Thursday, 17 October 2024
11:57	Why Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday?	benzinga.com
09:32	Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow	globenewswire.com
07:54	Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion	globenewswire.com
Tuesday, 15 October 2024
14:30	Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions	globenewswire.com
11:36	Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use	globenewswire.com

Frequently Asked Questions (FAQ)

What's the price of Tevogen Bio Holdings stock today?

One share of Tevogen Bio Holdings stock can currently be purchased for approximately $0.94.
When is Tevogen Bio Holdings's next earnings date?

Unfortunately, Tevogen Bio Holdings's (TVGN) next earnings date is currently unknown.
Does Tevogen Bio Holdings pay dividends?

No, Tevogen Bio Holdings does not pay dividends.
How much money does Tevogen Bio Holdings make?

Tevogen Bio Holdings has a market capitalization of 172.82M.
What is Tevogen Bio Holdings's stock symbol?

Tevogen Bio Holdings Inc. is traded on the NASDAQ under the ticker symbol "TVGN".
What is Tevogen Bio Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Tevogen Bio Holdings?

Shares of Tevogen Bio Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Tevogen Bio Holdings have?

As Dec 2024, Tevogen Bio Holdings employs 17 workers.
When Tevogen Bio Holdings went public?

Tevogen Bio Holdings Inc. is publicly traded company for more then 3 years since IPO on 5 Jan 2022.
What is Tevogen Bio Holdings's official website?

The official website for Tevogen Bio Holdings is tevogen.com.
Where are Tevogen Bio Holdings's headquarters?

Tevogen Bio Holdings is headquartered at 15 Independence Blvd, Warren, NJ.
How can i contact Tevogen Bio Holdings?

Tevogen Bio Holdings's mailing address is 15 Independence Blvd, Warren, NJ and company can be reached via phone at 877 838 6436.

Tevogen Bio Holdings Inc.

tevogen.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

877 838 6436

15 Independence Blvd
Warren, NJ 07059

CIK: 0001860871
ISIN: US88165K1016
: